Literature DB >> 6335017

Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

W T Hughes, B L Smith.   

Abstract

The purpose of this study was to identify new drugs for the prevention and treatment of Pneumocystis carinii pneumonitis (PCP) induced in rats by continuous daily dosage with dexamethasone. Initially, test drugs were administered prophylactically as a screen for efficacy. Drugs were selected because of their known activity against certain protozoa and their tolerance in human usage. Doses were based on previous studies in rats or estimated from usage in humans and lower animals. Allopurinol (50 mg/kg per day), ketoconazole (25 mg/kg per day), difluoromethylornithine (2.5 g/kg per day), diloxanide (125 mg/kg per day, nifurtimox (100 mg/kg per day), suramin (20 mg/kg per day), melarsoprol (20 mg/kg per day), gentian violet (0.5 mg/kg per week, 5 and 50 mg/kg per day), primaquine (5.6 mg/kg per day) and chloroquine (37.5 mg/kg per day) were ineffective, whereas diaminodiphenylsulfone (daspone) (25 mg/kg per day) was totally effective in preventing the infection. Diaminodiphenylsulfone was then evaluated at dose levels of 5, 25, and 125 mg/kg per day and compared with trimethoprim-sulfamethoxazole (TMP-SMZ), given at 50 per 250 mg/kg per day orally. The two highest dose levels of diaminodiphenylsulfone and TMP-SMZ prevented the infection in all of the animals, and the lowest dose of diaminodiphenylsulfone prevented it in 40% of the rats. All of the untreated controls developed PCP. To determine therapeutic efficacy, animals with extensive PCP were treated for 2.5 weeks with diaminodiphenylsulfone or TMP-SMZ. Based on residual extensive pneumonitis at the completion of treatment, the pneumonitis was reduced to 50% by TMP-SMZ and to 25% by diaminodiphenylsulfone, whereas 100% of untreated controls had extensive PCP. When treatment was begun earlier in the course of the pneumonitis, diaminodiphenylsulfone was totally effective in eradicating the infection. These results suggest that diaminodiphenylsulfone is an effective drug for the treatment and prevention of murine PCP and that it is at least as effective as TMP-SMZ.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335017      PMCID: PMC179940          DOI: 10.1128/AAC.26.4.436

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Adverse effects of dapsone.

Authors:  W R Graham
Journal:  Int J Dermatol       Date:  1975-09       Impact factor: 2.736

2.  A note on the treatment of strongyloidiasis with intravenous gentian violet.

Authors:  E D PALMER
Journal:  Am J Trop Med Hyg       Date:  1950-01       Impact factor: 2.345

3.  The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects.

Authors:  J H Peters; G R Gordon; D C Ghoul; J G Tolentino; G P Walsh; L Levy
Journal:  Am J Trop Med Hyg       Date:  1972-07       Impact factor: 2.345

4.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

5.  Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats.

Authors:  R M Kluge; D M Spaulding; A J Spain
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Antileishmanial effect of allopurinol. II. Relationship of adenine metabolism in Leishmania species to the action of allopurinol.

Authors:  J J Marr; R L Berens
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

7.  Antileishmanial effect of allopurinol.

Authors:  M A Pfaller; J J Marr
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

8.  Studies on the mechanism of the toxic action of diaminodiphenylsulfone (DDS) to mammals.

Authors:  D L Wu; K P DuBois
Journal:  Arch Int Pharmacodyn Ther       Date:  1970-01

9.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  39 in total

1.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 2.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs.

Authors:  M Viora; A De Luca; A D'Ambrosio; A Antinori; E Ortona
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii.

Authors:  D M Israelski; C Tom; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.

Authors:  W T Hughes
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  J Mills; G Leoung; I Medina; P C Hopewell; W T Hughes; C Wofsy
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

8.  Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.

Authors:  W T Hughes; D P Jacobus; C Canfield; J Killmar
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.

Authors:  W T Hughes; J Killmar
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.